Swine Patents (Class 800/17)
-
Patent number: 7893316Abstract: The invention concerns the reconstruction in vitro of non-human mammal embryos by a method which consists in treating the nucleus of a somatic donor cell prior to its transfer into a receiver cytoplasm, said treatment comprising controlled proteolysis of non-histone proteins, and inducing an isomorphic swelling of said nucleus.Type: GrantFiled: September 29, 2000Date of Patent: February 22, 2011Assignee: Institut National de la Recherche Agronomique (INRA)Inventors: Jean-Paul Renard, Xavier Vignon
-
Patent number: 7888321Abstract: A non-human transgenic mammalian animal, as described above, contains an exogenous double stranded DNA sequence stably integrated into the genome of the animal, which comprises cis-acting regulatory units operably linked to a DNA sequence encoding human FIX protein without the benefit of the presence of a complete milk gene sequence for gene rescue, and a signal sequence is active in directing newly expressed Factor IX into the milk of the animal at levels in an unactivated form that is suitable for subsequent processing for therapeutic applications in treating Hemophilia B. The transgenic mammals are preferably pigs, cows, sheep, goats and rabbits. The applications include milk derivatives for oral delivery and oral tolerization in the treatment of Hemophilia B.Type: GrantFiled: October 21, 2008Date of Patent: February 15, 2011Assignee: Progenetics LLCInventors: Julian D. Cooper, William Hugold Velander, Tanya K. O'Sickey
-
Publication number: 20110030078Abstract: The present invention is directed to a Trypanosome-resistant, non-human transgenic animal whose somatic and germ cells comprise a nucleic acid which encodes an apolipoprotein L-I polypeptide (apoL-I). The apoL-I protein has the amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5. The first nucleic acid transgene is operatively associated with at least one expression regulatory sequence. Methods of producing and raising such transgenic animals as well as transgenic eggs and sperm are also disclosed.Type: ApplicationFiled: August 2, 2010Publication date: February 3, 2011Applicant: NEW YORK UNIVERSITYInventors: Jayne RAPER, Russell THOMPSON, Marie SAMANOVIC, Maria Del Pilar Molina PORTELA
-
Publication number: 20110030072Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding immunodeficiency proteins. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding immunodeficiency proteins.Type: ApplicationFiled: July 23, 2010Publication date: February 3, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023151Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding ABC transporter proteins. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding ABC transporter proteins.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023147Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with cognitive disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Phil Simmons, Xiaoxia Cui
-
Publication number: 20110023141Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with Parkinson's disease. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to study PD development and screen agents for assessing their effect on progression or symptoms of PD.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023152Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with cognitive disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences associated with cognitive disorders.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023148Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with addiction disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequence encoding addiction-related proteins and the nucleic acids encoding said zinc finger nucleases. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for addiction and withdrawal side effects and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023143Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with neurodevelopmental disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023149Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences involved in tumor suppression. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequence involved in tumor suppression and the nucleic acids encoding the zinc finger nucleases. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences involved in tumor suppression.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023153Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with AD. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to study AD development and methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with AD.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023145Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with ASD. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to study ASD development and screen agents for assessing their effect on progression or symptoms of an ASD.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023146Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with a secretase disorder. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Phil Simmons, Xiaoxia Cui
-
Publication number: 20110023150Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences associated with schizophrenia. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequence associated with schizophrenia and the nucleic acids encoding said zinc finger nucleases. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences associated with schizophrenia.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023139Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal involved in cardiovascular disease. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequences involved in cardiovascular disease and the nucleic acids encoding said zinc finger nucleases. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110016545Abstract: The invention relates to enzymes having xylanase, mannanase and/or glucanase activity, e.g., catalyzing hydrolysis of internal ?-1,4-xylosidic linkages or endo-?-1,4-glucanase linkages; and/or degrading a linear polysaccharide beta-1,4-xylan into xylose. Thus, the invention provides methods and processes for breaking down hemicellulose, which is a major component of the cell wall of plants, including methods and processes for hydrolyzing hemicelluloses in any plant or wood or wood product, wood waste, paper pulp, paper product or paper waste or byproduct. In addition, methods of designing new xylanases, mannanases and/or glucanases and methods of use thereof are also provided. The xylanases, mannanases and/or glucanases have increased activity and stability at increased pH and temperature.Type: ApplicationFiled: August 1, 2008Publication date: January 20, 2011Applicant: VERENIUM CORPORATIONInventors: Kevin Gray, Reinhard Dirmeier
-
Publication number: 20110016541Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with nociception or taste disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 20, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110016540Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with trinucleotide repeat expansion disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 20, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110016543Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding inflammation-related proteins. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding inflammation-related proteins.Type: ApplicationFiled: July 23, 2010Publication date: January 20, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110016546Abstract: The present invention provides a genetically modified porcine or cell comprising at least one edited chromosomal sequence. In particular, the chromosomal sequence is edited using a zinc finger nuclease-mediated editing process. The disclosure also provides zinc finger nucleases that target specific chromosomal sequences in the porcine genome.Type: ApplicationFiled: July 23, 2010Publication date: January 20, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Joseph Bedell, Brian Buntaine, Xiaoxia Cui
-
Publication number: 20110016539Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with neurotransmission disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 20, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20100333218Abstract: A non-human transgenic mammalian animal, as described above, contains one or more exogenous double stranded DNA sequence(s) stably integrated into the genome of the animal, which comprises trans-acting regulatory units controlling expression of DNA sequences encoding proteins to be secreted into the milk of transgenic mammals. The DNA sequence of the trans-regulatory gene encodes transcriptional activating proteins, which are not secreted but made in a temporally controlled and mammary tissue specific manner. The DNA sequence containing the protein to be secreted in the milk is constructed on a separate gene sequence under the regulation of a minimal promoter and a trans-activation binding domain. The transgenic mammals are preferably pigs, cows, sheep, goats and rabbits. A related composition and method for making transgenic proteins which require specialized propeptides for proper post-translational processing is also described.Type: ApplicationFiled: May 24, 2010Publication date: December 30, 2010Applicant: PROGENETICS LLCInventors: Julian D. Cooper, Tanya K. O'Sickey, Stephen P. Butler
-
Publication number: 20100299770Abstract: The present invention provides compositions and methods for studying neuropathy. The compositions and methods provided herein are particularly useful for screening agents of therapeutic and/or diagnostic potential.Type: ApplicationFiled: June 12, 2008Publication date: November 25, 2010Inventors: Stephen M. Selkirk, Robert H. Miller
-
Publication number: 20100293624Abstract: This application is in the field of sialic acid chemistry, metabolism, antigenicity, and the production of transgenic non-human mammals with altered sialic acid production. More particularly, this application relates to N-glycolylneuraminic acid (Neu5Gc) being an immunogen in humans, and the production of Neu5Gc-free mammalian products for laboratory and human use.Type: ApplicationFiled: June 8, 2006Publication date: November 18, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Ajit Varki, Anna Maria Hedlund, Dzung Nguyen
-
Publication number: 20100281548Abstract: This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or remyelination. In addition, the invention relates to the generation of an animal model that exhibits hypomyelination. The compositions and methods embodied in the present invention are particularly useful for drug screening and/or treatment of demyelination disorders.Type: ApplicationFiled: April 28, 2010Publication date: November 4, 2010Applicant: UNIVERSITY OF CHICAGOInventors: Brian Popko, Wensheng Lin
-
Publication number: 20100251395Abstract: Transgenic pigs that express one or more non-porcine cytosine deaminases are described as well as methods of making and using such pigs.Type: ApplicationFiled: November 20, 2009Publication date: September 30, 2010Inventors: Reuben S. Harris, Stefan R. Jonsson, Scott C. Fahrenkrug, Rebecca St. Claire Larue
-
Patent number: 7803981Abstract: The invention features novel methods for the production of large quantities of xenogenous antibodies, such as human antibodies. Preferably, this result is effected by inactivation of IgM heavy chain expression and, optionally, by inactivation of Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of xenogenous antibodies (e.g., non-bovine antibodies), preferably human antibodies.Type: GrantFiled: June 20, 2007Date of Patent: September 28, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: James M. Robl, Philippe Collas, Eddie Sullivan, Poothappillai Kasinathan, Richard A. Goldsby, Yoshimi Kuroiwa, Kazuma Tomizuka, Isao Ishida, Barbara Osborne
-
Publication number: 20100235926Abstract: The present invention provides a hairless transgenic nonhuman animal used in the development of a therapy for dermatitis such as human atopic dermatitis and drug discovery. Specifically, the present invention provides a transgenic nonhuman animal, into which recombinant DNA comprising a heparin-binding EGF gene and a type 2 keratin gene promoter for regulating expression of the above gene has been introduced.Type: ApplicationFiled: February 8, 2006Publication date: September 16, 2010Inventors: Hiromichi Yonekawa, Toyoyuki Takada, Hiroshi Shitara, Yoshiaki Kikkawa, Rie Ishii, Kenji Kohno
-
Patent number: 7795493Abstract: The present invention is a porcine animal, tissue, organ, cells and cell lines, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha1,3GT). These animals, tissues, organs and cells can be used in xenotransplantation and for other medical purposes.Type: GrantFiled: August 21, 2003Date of Patent: September 14, 2010Assignee: Revivicor, Inc.Inventors: Carol J. Phelps, David L. Ayares
-
Publication number: 20100215658Abstract: The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to pox virus H3L envelope protein, and combinations thereof.Type: ApplicationFiled: October 6, 2008Publication date: August 26, 2010Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventor: SHINICHIRO KATO
-
Publication number: 20100205682Abstract: The present invention concerns methods and means to produce humanized antibodies from transgenic non-human animals. The invention specifically relates to novel immunoglobulin heavy and light chain constructs, recombination and transgenic vectors useful in making transgenic non-human animals expressing humanized antibodies, transgenic animals, and humanized immunoglobulin preparations.Type: ApplicationFiled: July 29, 2009Publication date: August 12, 2010Inventors: ROLAND BUELOW, Wim van Schooten, Josef Platzer
-
Publication number: 20100205680Abstract: The present invention provides a mammary gland-specific human erythropoietin expression (hEPO) vector, transgenic animal and method for producing human erythropoietin using the same. The inventive hEPO-expressing transgenic animals express a mammary gland-specific EPO at an extremely higher concentration than the convention method. The hEPO produced from inventive transgenic animals shows better stability and superior physiological activity than those of the same kind of commerally available protein. Therefore, the inventive hEPO-expressing transgenic animals can be effectively used for production of EPO showing a superior physiological activity than the existing EPO.Type: ApplicationFiled: August 8, 2007Publication date: August 12, 2010Inventor: Jin Hoi Kim
-
Publication number: 20100205681Abstract: A prognostic marker for breast cancer and a composition for inducing obesity are provided, wherein said marker and said composition comprise HCCR-1.Type: ApplicationFiled: July 6, 2007Publication date: August 12, 2010Inventors: Hyun-Kee Kim, Jin-woo Kim
-
Publication number: 20100199368Abstract: The present invention relates generally to novel molecules capable of, inter alia, modulating apoptosis in mammalian cells and to genetic sequences encoding same. More particularly, the present invention relates to a novel member of the Bcl-2 family of proteins, referred to herein as “Bmf”, and to genetic sequences encoding same and to regulatory sequences such as a promoter sequence directing expression of Bmf. Bmf comprises a BH3 domain which facilitates interaction to pro-survival Bcl-2 family members thereby triggering apoptosis. Bmf is regarded, therefore, as a BH3-only molecule. The molecules of the present invention are useful, for example, in therapy, diagnosis, antibody generation and as a screening tool for therapeutic agents capable of modulating physiological cell death or survival and/or modulating cell cycle entry.Type: ApplicationFiled: July 7, 2009Publication date: August 5, 2010Applicant: The Walter And Eliza Hall Institute Of Medical ResearchInventors: Andreas STRASSER, Hamsa PUTHALAKATH, Andreas VILLUNGER, Leigh COULTAS, Jennifer BEAUMONT, Lorraine Ann O'REILLY, David Ching Siang HUANG
-
Publication number: 20100154069Abstract: The present invention relates to a genetically modified pig comprising at least one site for integration of at least one transgene. The invention also pertains to a porcine embryo, blastocyst, foetus, donor cell and/or cell nucleus, derived from said genetically modified pig. In another aspect, the invention relates to any genetically modified porcine blastocyst, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.Type: ApplicationFiled: March 7, 2008Publication date: June 17, 2010Applicant: AARHUS UNIVERSITETInventors: Jacob Giehm Mikkelsen, Brian Moldt, Anders Lade Nielsen, Lars Axel Bolund, Peter Michael Kragh, Jannik Ejnar Jakobsen, Arne Lund Jørgensen
-
Patent number: 7737325Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-modulated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: GrantFiled: May 18, 2005Date of Patent: June 15, 2010Assignee: Kyowa Hakko Kirin Co., LtdInventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
-
Publication number: 20100146655Abstract: Transgenic artiodactyls are described as well as methods of making and using such artiodactyls.Type: ApplicationFiled: July 16, 2009Publication date: June 10, 2010Inventors: SCOTT C. FAHRENKRUG, DANIEL F. CARLSON, ARON M. GEURTS
-
Publication number: 20100136113Abstract: This invention relates to phytases, polynucleotides encoding them, uses of the polynucleotides and polypeptides of the invention, as well as the production and isolation of such polynucleotides and polypeptides. In particular, the invention provides polypeptides having phytase activity under high temperature conditions, and phytases that retain activity after exposure to high temperatures. The phytases of the invention can be thermotolerant and/or thermostable at low temperatures, in addition to higher temperatures. The phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be formulated as foods or feeds or supplements for either to, e.g., aid in the digestion of phytate. The foods or feeds of the invention can be in the form of pellets, liquids, powders and the like.Type: ApplicationFiled: September 21, 2007Publication date: June 3, 2010Applicant: VERENIUM CORPORATIONInventors: Brian Steer, Mark Dycaico, Katie A. Kline, Axel Trefzer, Thomas Todaro, Arne Solbak, Fatima El-Farrah, Alberto Alvarado, Gerhard Frey
-
Publication number: 20100125918Abstract: The invention provides a new type of a capsid protein VP1 of human enterovirus 71, named as MEL701-VP1 and functional/structural variants thereof, which is used for protection against enterovirus. The transgenic animal producing the protein, the composition comprising the protein and the method for production thereof are also provided.Type: ApplicationFiled: November 19, 2008Publication date: May 20, 2010Applicant: National Chung Hsing UniversityInventors: Chuan-Mu Chen, Hsiao-Ling Chen
-
Publication number: 20100115640Abstract: Methods are disclosed in which the expression of a specific gene, or combinations of genes, is controlled spatially and temporally to develop intra- and interspecies chimeras. A transgenic EC/ES/P/iPS cell line is created which conditionally expresses a suicide or compromiser gene configured to compromise all cell lineages except that corresponding to a target tissue/organ. The EC/ES/P/iPS cell line is injected into donor embryos having a specific target gene deficiency or embryos genetically engineered to be complementary compromised in lineages corresponding to the target tissue/organ cell lineages of the EC/ES/P/iPS line. One or more stimuli is provided to the embryo to activate compromiser genes for ablation of non-target tissues/organs of the EC/ES/P/iPS line and target tissues/organs of the host embryo, resulting in a chimeric animal having target tissues/organs derived from the genotype of the transgenic cell line and all remaining tissues/organs derived from the donor embryo.Type: ApplicationFiled: March 7, 2008Publication date: May 6, 2010Applicant: THE CURATORS OF THE UNIVERSITY OF MISSOURIInventors: Chongbei Zhao, Andras Nagy, John K. Critser
-
Publication number: 20100115641Abstract: Disclosed are a cloned pig expressing green fluorescent protein (GFP) and a cloned pig having a 1,3-galactosyltransferase (GT) gene knocked out. Also, the present invention discloses methods of producing such cloned pigs, comprising the steps of establishing a somatic cell line; preparing a GFP-transfected or GT gene knock-out nuclear donor cell; producing a transgenic nuclear transfer embryo using the nuclear donor cell and a recipient oocyte; and transplanting the transgenic nuclear transfer embryo into a surrogate mother pig. The cloned pig expressing GFP of the present invention is useful for large-scale production of an animal disease model, and the GT gene knock-out cloned pig can be used as a organ donor allowing xenotransplantation in humans without hyperacute immune rejection.Type: ApplicationFiled: October 14, 2009Publication date: May 6, 2010Applicant: SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATIONInventors: So H. Lee, Woo S. Hwang, Byeong C. Lee, Sung K. Kang, Jek Y. Han, Jeong M. Lim, Chang K. Lee, Eun S. Lee, Eui B. Jeung, Jong K. Cho, Dae Y. Kim, Sang H. Hyun, Gab S. Lee, Hye S. Kim, Sung C. Lee, Su C. Yeom
-
Publication number: 20100107263Abstract: The instant invention relates to a transgenic, non-human animal that carries a mutation in the gene encoding C-reactive protein (CRP). Preferably, the invention relates to an animal comprising a homozygous CRP-deficient mouse and techniques for producing such animals. The invention also relates to organs, tissues, cells, cell lines and sub-cellular fractions derived from such animals. Techniques for generating total or tissue-specific CRP knockout animals are also described. The invention further relates to the use of such knockout animals for the study of the role of CRP proteins in vivo or ex vivo, particularly in relation to its role in inflammatory pathway and in the etiology human diseases.Type: ApplicationFiled: January 22, 2008Publication date: April 29, 2010Applicant: Boehringer Ingelheim International GMBH & co., KGInventors: Steven Kerr, Huiping Jiang, Jeffrey Madwed
-
Publication number: 20100088778Abstract: A method for the diagnosis of an epilepsy syndrome, including SMEI or an SMEI-related syndrome, in a patient comprising testing for an alteration in the SCN1A gene in a sample obtained from the patient; and if an alteration is identified, comparing said alteration to any one of those listed in Table 3, wherein if said alteration is identical to any one of those listed in Table 3, a diagnosis of an epilepsy syndrome, including SMEI or an SMEI-related syndrome, in said patient is made in accordance with the correlation set forth in Table 3.Type: ApplicationFiled: June 16, 2006Publication date: April 8, 2010Inventors: John Charles Mulley, Louise Harkin, Samuel Frank Berkovic, Ingrid Eileen Scheffer, Steven Petrou
-
Publication number: 20100077491Abstract: Provided herein are compositions and methods relating to the involvement of RNF5 in muscle wasting.Type: ApplicationFiled: July 12, 2007Publication date: March 25, 2010Applicants: Burnham Institute for Medical Research, Mount Sinai School of MedicineInventors: Ze'ev Ronai, Agnes DeLaunay, Kenneth Bromberg
-
Enhanced production of cloned mammals by zona pellucida-free homologous mammalian embryo aggregation
Patent number: 7683236Abstract: Compositions and methods are provided for the efficient and reproducible generation of clone animals of all developmental stages. Also provided are methods of use of the same in reproductive and therapeutic cloning protocols.Type: GrantFiled: June 10, 2004Date of Patent: March 23, 2010Assignee: Trustees of the University of PennsylvaniaInventors: Michele Boiani, Kenneth John McLaughlin, Hans R. Scholer -
Publication number: 20100061997Abstract: The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of modulating an effect of myostatin on a cell by contacting the cell with an agent that affects myostatin signal transduction in the cell. In addition, the invention provides a method of ameliorating the severity of a pathologic condition, which is characterized, at least in part, by an abnormal amount, development or metabolic activity of muscle or adipose tissue in a subject, by modulating myostatin signal transduction in a muscle cell or an adipose tissue cell in the subject.Type: ApplicationFiled: January 28, 2009Publication date: March 11, 2010Inventors: Se-Jin Lee, Alexandra C. McPherron
-
Patent number: 7667089Abstract: Hemophilia A is one of the major inherited bleeding disorders caused by a deficiency or abnormality in coagulation factor VIII (FVIII). Hemophiliacs have been treated with whole plasma or purified FVIII concentrates. The risk of transmitting blood-borne viruses and the cost of highly purified FVIII are the major factors that restrict prophylaxis in hemophilia therapy. One of the challenges created by the biotechnology revolution is the development of methods for the economical production of highly purified proteins in large scales. The present invention provides improved mammary expression cassettes useful for the expression of genes at high levels in the milk of transgenic animals. In particular, the present invention provides recombinant signal peptide sequences derived from a-lactalbumin and aS1-casein milk genes suitable for leading protein secretion in the mammary gland.Type: GrantFiled: April 9, 2004Date of Patent: February 23, 2010Assignee: National Chung Hsing UniversityInventors: Winston T. K. Cheng, Chuan-Mu Chen, Shwu-Wha Lin, Chih-Hong Wang, Chih-Jen Lin, Shinn-Chih Wu
-
Patent number: 7652192Abstract: The invention is directed in part to totipotent cells that have one or more artificial chromosomes; processes for producing such cells; processes for using such cells (e.g., nuclear transfer); transgenic embryos and transgenic animals cloned from such cells; and processes for producing such embryos and animals.Type: GrantFiled: February 21, 2002Date of Patent: January 26, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Erik J. Forsberg, Kelly S. Mallon, Paul J. Golueke, Michael D. Bishop
-
Publication number: 20100011456Abstract: The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. Polypeptides, including enzymes and antibodies, and nucleic acids of the invention can be used in industrial, experimental, food and feed processing, nutritional and pharmaceutical applications, e.g., for food and feed supplements, colorants, neutraceuticals, cosmetic and pharmaceutical needs.Type: ApplicationFiled: March 3, 2006Publication date: January 14, 2010Applicant: Verenium CorporationInventors: Eric J. Mathur, Cathy Chang